Targeting the seeds of small cell lung cancer

Sylvia Mahara, Ron Firestein

Research output: Contribution to journalArticleOtherpeer-review

Abstract

The concept of antibody drug conjugates (ADCs), which includes the delivery of cytotoxic drugs to antigen-expressing tumor cells by harnessing the antigen-selectivity of a monoclonal antibody, has the potential to redefine the landscape of translational medicine. With the advent of patient derived xenograft (PDX) models and sophisticated genomic technologies, the identification of a selective antigen can be accurately validated within the appropriate tumor milieu. However, a major biological hurdle in cancer translational medicine is the inherent tumoral heterogeneity, underscoring the importance of targeting the 'right' sub-population of cancer cells. Herein, we review a seminal work highlighting the ability to target a key 'stem-like' cancer sub-population called tumor initiating cells (TICs) using engineered ADCs. While the promise of this approach needs to be validated in the clinical setting, TIC-targeted ADCs offer great hope for circumventing current limitations with conventional ADC therapy.

Original languageEnglish
Article number113
JournalAnnals of Translational Medicine
Volume5
Issue number5
DOIs
Publication statusPublished - 1 Mar 2017

Keywords

  • Antibody drug conjugates (ADCs)
  • Cancer
  • Stem cells
  • Tumor initiating cells (TICs)

Cite this

@article{cb36e2dfcf734ca6909bf6f5e52ef430,
title = "Targeting the seeds of small cell lung cancer",
abstract = "The concept of antibody drug conjugates (ADCs), which includes the delivery of cytotoxic drugs to antigen-expressing tumor cells by harnessing the antigen-selectivity of a monoclonal antibody, has the potential to redefine the landscape of translational medicine. With the advent of patient derived xenograft (PDX) models and sophisticated genomic technologies, the identification of a selective antigen can be accurately validated within the appropriate tumor milieu. However, a major biological hurdle in cancer translational medicine is the inherent tumoral heterogeneity, underscoring the importance of targeting the 'right' sub-population of cancer cells. Herein, we review a seminal work highlighting the ability to target a key 'stem-like' cancer sub-population called tumor initiating cells (TICs) using engineered ADCs. While the promise of this approach needs to be validated in the clinical setting, TIC-targeted ADCs offer great hope for circumventing current limitations with conventional ADC therapy.",
keywords = "Antibody drug conjugates (ADCs), Cancer, Stem cells, Tumor initiating cells (TICs)",
author = "Sylvia Mahara and Ron Firestein",
year = "2017",
month = "3",
day = "1",
doi = "10.21037/atm.2017.01.74",
language = "English",
volume = "5",
journal = "Annals of Translational Medicine",
issn = "2305-5847",
number = "5",

}

Targeting the seeds of small cell lung cancer. / Mahara, Sylvia; Firestein, Ron.

In: Annals of Translational Medicine, Vol. 5, No. 5, 113, 01.03.2017.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Targeting the seeds of small cell lung cancer

AU - Mahara, Sylvia

AU - Firestein, Ron

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The concept of antibody drug conjugates (ADCs), which includes the delivery of cytotoxic drugs to antigen-expressing tumor cells by harnessing the antigen-selectivity of a monoclonal antibody, has the potential to redefine the landscape of translational medicine. With the advent of patient derived xenograft (PDX) models and sophisticated genomic technologies, the identification of a selective antigen can be accurately validated within the appropriate tumor milieu. However, a major biological hurdle in cancer translational medicine is the inherent tumoral heterogeneity, underscoring the importance of targeting the 'right' sub-population of cancer cells. Herein, we review a seminal work highlighting the ability to target a key 'stem-like' cancer sub-population called tumor initiating cells (TICs) using engineered ADCs. While the promise of this approach needs to be validated in the clinical setting, TIC-targeted ADCs offer great hope for circumventing current limitations with conventional ADC therapy.

AB - The concept of antibody drug conjugates (ADCs), which includes the delivery of cytotoxic drugs to antigen-expressing tumor cells by harnessing the antigen-selectivity of a monoclonal antibody, has the potential to redefine the landscape of translational medicine. With the advent of patient derived xenograft (PDX) models and sophisticated genomic technologies, the identification of a selective antigen can be accurately validated within the appropriate tumor milieu. However, a major biological hurdle in cancer translational medicine is the inherent tumoral heterogeneity, underscoring the importance of targeting the 'right' sub-population of cancer cells. Herein, we review a seminal work highlighting the ability to target a key 'stem-like' cancer sub-population called tumor initiating cells (TICs) using engineered ADCs. While the promise of this approach needs to be validated in the clinical setting, TIC-targeted ADCs offer great hope for circumventing current limitations with conventional ADC therapy.

KW - Antibody drug conjugates (ADCs)

KW - Cancer

KW - Stem cells

KW - Tumor initiating cells (TICs)

UR - http://www.scopus.com/inward/record.url?scp=85015231158&partnerID=8YFLogxK

U2 - 10.21037/atm.2017.01.74

DO - 10.21037/atm.2017.01.74

M3 - Article

VL - 5

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

SN - 2305-5847

IS - 5

M1 - 113

ER -